Bristol-Myers Squibb Company PFD CONV 2 Receivables

The latest receivables for BMYMP is $11B as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Bristol-Myers Squibb Company PFD CONV 2's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMYMP's receivables moved from $0 to $11B. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb Company PFD CONV 2's operating scale or balance-sheet position.

A receivables figure of $11B for BMYMP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BMYMP's receivables ($11B), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bristol-Myers Squibb Company PFD CONV 2's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.